logo
Plus   Neg
Share
Email

Novavax, Takeda To Develop Novavax' COVID-19 Vaccine Candidate In Japan - Quick Facts

Biotechnology company Novavax, Inc. (NVAX) and Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Friday a partnership for the development, manufacturing and commercialization of Novavax' COVID-19 vaccine candidate NVX-CoV2373 in Japan.

NVX-CoV2373 is a stable, prefusion protein made using Novavax' recombinant protein nanoparticle technology and includes Novavax' proprietary Matrix-M adjuvant. The vaccine candidate is engineered from the genetic sequence of SARS-CoV-2.

Novavax will license and transfer manufacturing technologies to enable Takeda to manufacture the vaccine antigen and will supply the Matrix-M adjuvant to Takeda.

Takeda will be responsible for regulatory submission to the MHLW and will produce and distribute NVX-CoV2373 in Japan. It anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year.

Meanwhile, Novavax will be entitled to receive payments based on the achievement of certain development and commercial milestones, as well as a portion of proceeds from the vaccine.

Takeda will receive funding from the Government of Japan's Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure and scale-up of manufacturing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pizza Hut's large Original Pan Pizza is now available at locations across the U.S. for $10.99. The fast food chain, a subsidiary of Yum! Brands Inc., said that fans can now get a large Original Pan Pizza with up to three of their favorite toppings, without needing to stretch their wallets. The Original Pan Pizza is a buttery golden-brown color. The U.S. Food and Drug Administration approved the first drug to treat adults and children aged 12 years and older with hypereosinophilic syndrome for six months or longer without another identifiable non-blood related cause of the disease. GlaxoSmithKline's Nucala (mepolizumab) is the first FDA-approved drug in nearly 14 years to treat this group of rare and debilitating blood diseases. Uber has won a legal battle to continue to operate in London, one of its largest markets. The ride-hailing company has been granted an 18-month license to operate in London after overturning the ban on an appeal for the second time. The Westminister Magistrates Court found Uber London Ltd. a "fit and proper" company to run the services in London.
Follow RTT